Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 6 7 8 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Immunicum–Trophic Communications: public relations, 201801 service existent IR + media relations EU + US by Trophic 2018-01-31
STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen 2018-01-31
eTherapists–Creathor Venture: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al 2018-01-30
eTherapists–SEVERAL: investment, 201801 financing round 7-digit € for Humanoo.com from Creathor + DvH Ventures et al 2018-01-30
Helsinn–Scientific Centre of Monaco: cancer drug, 201801– collab research new pharmacological inhibitors for clear cell renal cell carcinoma 2018-01-30
Ablynx–Sanofi: investment, 201801–201806 acquisition recommended cash tender offer €3.9b with €45/share 2018-01-29
Clariant–SABIC: investment, 201801 acquisition 24.99% shareholding by SABIC via acquisition of shares previously held by White Tale + 40 North 2018-01-25
Topas Therapeutics–Univ Hamburg: anti-inflammatory drugs, 201801– collab Topas excl translational partner for liver inflammation CRC at UKE 2018-01-25
ImmuPharma–SEVERAL: investment, 201801 placing £10m of 6.945m new ordinary shares at 144p/share 2018-01-24
Nebion–Qlucore: genomic software tools, 201801– collab integration of Qlucore Omics Explorer s/w + Genevestigator s/w for gene expression analysis 2018-01-24
Novartis–Spark Therapeutics: voretigene neparvovec, 201801– license ww outside US to develop + register + commerc gene therapy Luxtarna 2018-01-24
High-Tech Gründerfonds–Dräger: investment, 201801 investment of Dräger in HTGF III Fund 2018-01-23
Juno Therapeutics–Celgene: investment, 201801–201803 acquisition cash tender offer $9b net of cash + shares already owned by Celgene $87/share 2018-01-22
Novartis–Biocon: biosimilars, 201801– collab strategic ww excl developm + production + comercialisation Sandoz + Biocon 2018-01-18
Cellnovo–Flextronics: contract manufacturing, 201801 supply existent production of Cellnovo Diabetes Monitoring System + Cartridges by Flex 2018-01-17
Eximmium–Helmholtz: investment, 201801 seed funding €250k from Helmholtz Enterprise + Helmholtz Zentrum München at spin off of Eximmium 2018-01-17
Sartorius–Synpromics: genomic technology, 201801 collab existent with Sartorius Stedim Cellca 2018-01-17
Owkin–SEVERAL: investment, 201801 financing round Series A $11m led by Otium Venture + incl Cathay Innovation + Plug and Play + NJF Capital 2018-01-16
Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte 2018-01-11
Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED 2018-01-11
Structural Genomics Consortium–Enamine: chemical compound libraries, 201801– supply new generation of Diamond-SGC-iNEXT (DSI) Poised Library 2018-01-10
BeiGene–Boehringer: biopharmaceuticals, 201801– supply manufacturing of tislelizumab by Boehringer in Shanghai 2018-01-09
BioNTech–Scancell: cancer immunotherapy, 201801– collab research using Moditope platform w excl license option for BioNTech 2018-01-09
General Electric–Roche: diagnostics, 201801– collab developm integrated digital + IVD + in vivo diagnostics platform for oncology + critical care 2018-01-08
Indivumed–EU (govt): credit, 201801– EIB/EFSI grant €40m to create Global Cancer Database Solution 2018-01-08
TiGenix–Takeda: investment, 201801– aquisition public cash takeover offer €520m for remaining 95.8% for €1.78/share 2018-01-05
BioNTech–Fidelity: investment, 201801 financing round Series A totalling $270m incl new + co-investor Fidelity Management & Research 2018-01-04
BioNTech–Invus Group: investment, 201801 financing round Series A totalling $270m incl new + co-investor Invus 2018-01-04
BioNTech–Janus Henderson: investment, 201801 financing round Series A totalling $270m incl new + co-investor Janus Henderson Investors 2018-01-04
BioNTech–Redmile Group: investment, 201801 financing round Series A totalling $270m incl new + lead investor Redmile Group LLC 2018-01-04
BioNTech–SEVERAL: investment, 201801 financing round Series A $270m led by new investor Redmile Group LLC 2018-01-04
BioNTech–Strüngmann Group: investment, 201801 financing round Series A totalling $270m incl returning co-investor Strüngmann Family Office 2018-01-04
CureVac–Arcturus Therapeutics: mRNA therapeutics, 201801– strategic collab for lipid-mediated mRNA drugs using RNAoptimizer + LUNAR system 2018-01-04
CureVac–BMC Communications: public relations, 201801 service existent by BMC 2018-01-04
Enterome–BPCE: investment, 201801 financing round Series D totalling €32m incl existing investor Seventure + Health for Life Capital 2018-01-04
Enterome–Lundbeck: investment, 201801 financing round Series D totalling €32m incl existing investor LundbeckFonden Ventures 2018-01-04
Enterome–Nestlé: investment, 201801 financing round Series D totalling €32m incl existing investor Nestlé Health Science 2018-01-04
Enterome–SEVERAL: investment, 201801 financing round Series D €32m incl Seventure + Health for Life Capital + Lundbeck Fonden + Omnes Capital et al 2018-01-04
Miracor–SEVERAL: investment, 201801 financing round Series D €25m incl equity + debt + cash advance grant from Walloon govt 2018-01-04
Oculis–Bay City Capital: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Bay City Capital 2018-01-04
Oculis–Brunnur Ventures: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Brunnur Ventures 2018-01-04
Oculis–Huntsworth: public relations, 201801 service existent by Citigate Dewe Rogerson 2018-01-04
Oculis–Nan Fung: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Pivotal BioVenture Partners 2018-01-04
Oculis–Novartis: investment, 201801 financing round Series B totalling CHF20m incl new + co-lead investor Novartis Venture Fund 2018-01-04
Oculis–SEVERAL: investment, 201801 financing round Series B CHF20m led by Bay City Capital + NVF + Pivotal BioVenture Partners 2018-01-04
Oculis–Silfurberg: investment, 201801 financing round Series B totalling CHF20m incl existing + co-investor Silfurberg 2018-01-04
Rewind Therapeutics–Boehringer: investment, 201801 financing round Series A totalling €15.2m incl co-lead investor BIVF 2018-01-04
Rewind Therapeutics–Flanders (govt): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor PMV 2018-01-04
Rewind Therapeutics–Merck (DE): investment, 201801 financing round Series A totalling €15.2m incl co-lead investor Merck Ventures 2018-01-04
Rewind Therapeutics–SEVERAL: investment, 201801 financing round Series A €15.2m led by BIVF + Merck Ventures + PMV 2018-01-04
Rewind Therapeutics–Univ Leuven: investment, 201801 financing round Series A totalling €15.2m incl co-investors KU Leuven CD3 + KU Leuven GFF 2018-01-04
Themis Bioscience–SEVERAL: investment, 201801 financing round Series C €10m led by new investor GHIF 2018-01-04
Themis Bioscience–Trophic Communications: public relations, 201801 service existent by Trophic 2018-01-04
BASF–Biocrates: investment, 201801 acquisition of Metanomics Health GmbH by Biocrates from BASF Plant Science GmbH 2018-01-03
Biocrates–BASF: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–MIG Fonds: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–SEVERAL: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Biocrates–Xolaris Service KVG: investment, 201801 financing round incl BASF Plant Science GmbH + MIG Fonds + GA Asset Fund 2018-01-03
Centogene–MacDougall Biomedical Communications: public relations, 201801 service existent by MacDougall 2018-01-03
CRISPR Therapeutics–SEVERAL: investment, 201801 public offering $113.75m of 5m+750k common shares at $22.75/share 2018-01-03
Indivior–Addex: ADX71441, 201801– license + collab agreem $5m upfront + $4m research funding + $330m milestones plus royalties 2018-01-03
Central BioHub–in.vent Diagnostica: in vitro diagnostics, 201801 collab existent 2018-01-02
Clariant–Global Bioenergies: biopolymers, –201801 collab developm bio-based polymers for cosmetics developed w sugar-based isobutene 2018-01-02
European Pharma Oligonucleotide Consortium–AstraZeneca: oligonucleotide drugs, 2018– collab AstraZeneca is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Biogen: oligonucleotide drugs, 2018– collab Biogen is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–GSK: oligonucleotide drugs, 2018– collab GSK is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–JnJ: oligonucleotide drugs, 2018– collab Janssen is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Roche: oligonucleotide drugs, 2018– collab Roche is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Sanofi: oligonucleotide drugs, 2018– collab Sanofi is founding member of EPOC 2018-01-01
Siemens–OTHER: investment, 2018H1 PLANNED listing of newSiemens Healthineers AG at Frankfurt Stock Exchange 2018-01-01
BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US 2017-12-21
Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share 2017-12-21
Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties 2017-12-20
Boehringer–Autifony: CNS drugs, 201712– collab €25m upfront + up to total of €627.5m excl option to acquire KV3.1/3.2 positive modulators for BI 2017-12-18
Danaher–Cotecna: mass spectrometry, –201712 collab developm LC-MS/MS method for pesticide detection by Sciex + NofaLab 2017-12-18
Roche–Horizon Discovery: reference standards, 201712– collab developm + supply of FFPE reference standards for ICH-NTRK assays for Roche Dx 2017-12-18
Fast Track Diagnostics–Siemens: investment, 201712 acquisiton €na of FTD by Siemens Healthineers 2017-12-15
Evotec–TU Dresden: drug discovery, 201712– collab research €na small-molecule candidates for retinal diseases using iPSC technology with CRTD 2017-12-13
Flexion Therapeutics–GeneQuine: gene therapy, 201712 acquisition $2m upfront + $62.7m milestones + royalties ww rights to GQ-203 by Flexion 2017-12-13
NorthSea Therapeutics–BASF: icosabutate, 201712– license from Pronova BioPharma Norge AS 2017-12-12
NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures 2017-12-12
Oncgnostics–SEVERAL: investment, 201712–201801 crowdfunding campaign €750k via Seedmatch platform 2017-12-12
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF 2017-12-11
Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF 2017-12-11
Aelin Therapeutics–Flanders (govt): investment, 201712 financing round Series A totalling €27m incl investor PMV 2017-12-11
Aelin Therapeutics–Fund+: investment, 201712 financing round Series A totalling €27m incl investor Fund+ 2017-12-11
Aelin Therapeutics–Life Sciences Partners: investment, 201712 financing round Series A totalling €27m incl lead investor LSP 2017-12-11
Aelin Therapeutics–Novartis: investment, 201712 financing round Series A totalling €27m incl investor Novartis Venture Fund 2017-12-11
Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+ 2017-12-11
Boehringer–AbeXXa Biologics: drug target research, 201712 collab existent to identify molecular protein targets for cancer 2017-12-11
Boehringer–Univ California: cancer vaccine, 201712 collab existent to develop vaccine technology platform with UCLA 2017-12-11
Hookipa–BioMedPartners: investment, 201712 financing round Series C totalling €50m incl returning investor BioMedPartners 2017-12-11
Hookipa–Boehringer: investment, 201712 financing round Series C totalling €50m incl returning investor BIVF 2017-12-11
Hookipa–Forbion: investment, 201712 financing round Series C totalling €50m incl returning investor Forbion Capital Partners 2017-12-11
Hookipa–Gilead: investment, 201712 financing round Series C totalling €50m incl new + strategic investor Gilead 2017-12-11
Hookipa–HBM: investment, 201712 financing round Series C totalling €50m incl new investor HBM Partners 2017-12-11
Hookipa–Hillhouse Capital: investment, 201712 financing round Series C totalling €50m incl new investor Hillhouse Capital 2017-12-11
Hookipa–OTHER: investment, 201712 financing round Series C totalling €50m incl undisclosed US public investment fund as new + lead investor 2017-12-11
Hookipa–SEVERAL: investment, 201712 financing round Series C €50m led by undisclosed US public investment fund 2017-12-11
next pagenext page 1 2 3 ... 6 7 8 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top